Fulgent Genetics, Inc.
Fulgent Genetics, Inc. (Nasdaq: FLGT) provides laboratory testing and develops cancer therapeutics. Its laboratory services include anatomic pathology, precision diagnostics such as next-generation sequencing for rare disease, hereditary cancer and reproductive health, specialized oncology testing, and testing and… From the company’s description.
Over the twelve months to Sep 30, 2026, Fulgent Genetics, Inc. reported revenue of $330.27M, up 4.7% from a year earlier, and a net loss of $91.98M. Its operating margin was −39.2%, and operations generated $14.43M in cash. In fiscal 2025, it reported revenue of $322.67M, up 13.8% from fiscal 2024, and a net loss of $61.63M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fulgent Genetics, Inc. does
In the company’s own words
Fulgent Genetics, Inc. (Nasdaq: FLGT) provides laboratory testing and develops cancer therapeutics. Its laboratory services include anatomic pathology, precision diagnostics such as next-generation sequencing for rare disease, hereditary cancer and reproductive health, specialized oncology testing, and testing and licensing services for pharmaceutical and biotechnology companies. The Picture platform offers consumers telemedicine-supported testing. Customers include insurers, hospitals and other institutions, laboratories, government bodies, corporations, and patients paying directly. The company also develops nanoencapsulated drug candidates intended to treat cancers, including FID-007 and FID-022. Its two principal businesses are laboratory services and therapeutic development; Fulgent Pharma entered the company through a 2022 acquisition, and the 2025 acquisition of ANP Technologies brought ownership of previously licensed drug-delivery patents and platforms. In 2025, revenue totaled $321 million. Its brands include Fulgent, Picture Genetics, Picture, BEACON, INFORMDX, LUMERA, and KNOVA. Its website is https://www.fulgentgenetics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- EL MONTE, CA
- Fiscal year end
- December
- CIK
- 1674930
- SIC
- 8071
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fulgent Genetics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fulgent Genetics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fulgent Genetics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fulgent Genetics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fulgent Genetics, Inc.'s last four quarterly filings that the numbers alone won't show?”